4.44
1.55%
-0.07
Handel nachbörslich:
4.4018
-0.0382
-0.86%
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
A company insider recently bought 54321 shares of Summit Therapeutics Inc [SMMT]. Should You Buy? – Knox Daily - Knox Daily
Knox Daily
Summit Therapeutics Inc’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
The InvestChronicle
Financial Snapshot: Analyzing Summit Therapeutics Inc (SMMT)'s Key Ratio Metrics – DWinneX - The Dwinnex
The Dwinnex
A significant driver of top-line growth: Summit Therapeutics Inc (SMMT) – Sete News - SETE News
SETE News
Understanding the Risks of Investing in Summit Therapeutics Inc (SMMT) – Knox Daily - Knox Daily
Knox Daily
Zurcher Kantonalbank Zurich Cantonalbank Acquires 14098 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Defense World
Summit Therapeutics (NASDAQ:SMMT) Coverage Initiated by Analysts at Citigroup - Defense World
Defense World
Summit Therapeutics (NASDAQ:SMMT) Sets New 1-Year High at $5.39 - MarketBeat
MarketBeat
Summit: A Few Catalysts In Q2 Of 2024 To Carry The Tide (NASDAQ:SMMT) - Seeking Alpha
Seeking Alpha
Federated Hermes Inc. Reduces Position in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Defense World
Federated Hermes Inc. Reduces Position in Summit Therapeutics Inc. (NASDAQ:SMMT) - Defense World
Defense World
Summit Therapeutics (NASDAQ:SMMT) Shares Up 8.7% - MarketBeat
MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Now Covered by Analysts at Citigroup - MarketBeat
MarketBeat
Summit spikes as Citi launches at Buy on lead asset - MSN
MSN
Summit spikes as Citi launches at Buy on lead asset (NASDAQ:SMMT) - Seeking Alpha
Seeking Alpha
Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer - citybiz
citybiz
Summit Therapeutics (NASDAQ:SMMT) Now Covered by Analysts at Citigroup - MarketBeat
MarketBeat
Summit Therapeutics' Ivonescimab: Strong Buy; Dual-Action Approach To Cancer (NASDAQ:SMMT) - Seeking Alpha
Seeking Alpha
Summit Therapeutics' Ivonescimab: Strong Buy; Dual-Action Approach To Cancer (NASDAQ:SMMT) - Seeking Alpha
Seeking Alpha
SHAREHOLDER ALERT: Potential Recovery for Summit Therapeutics Inc. (SMMT) Investors - MSN
MSN
Insiders Of Summit Therapeutics Reap Rewards After Their Investment Jumps Another US$8.3m - Simply Wall St
Simply Wall St
Summit Therapeutics Inc (SMMT) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights and Financial Health - GuruFocus.com
GuruFocus.com
Earnings call: Summit Therapeutics reports on ivonescimab trials - Investing.com India
Investing.com India
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.6% - MarketBeat
MarketBeat
Summit Therapeutics Inc (SMMT) looking to reclaim success with recent performance – Sete News - SETE News
SETE News
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024 ... - wallstreet:online
wallstreet:online
Summit Therapeutics (NASDAQ:SMMT) Trading 3.6% Higher - MarketBeat
MarketBeat
Summit Therapeutics Inc (SMMT)'s stock rises to 3.88 per share – US Post News - US Post News
US Post News
Summit Therapeutics Inc (SMMT)'s stock rises to 3.88 per share – US Post News - US Post News
US Post News
Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024 - Business Wire
Business Wire
Wall Street Breakfast: The Week Ahead
Seeking Alpha
Summit Therapeutics Appoints Biotech Veteran to Board - TipRanks.com - TipRanks
TipRanks
Summit Therapeutics appoints genomics expert to board By Investing.com - Investing.com
Investing.com
Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor - WTAQ
WTAQ
Summit Therapeutics Announces Major Leadership Restructuring - TipRanks.com - TipRanks
TipRanks
Summit Therapeutics CFO Ankur Dhingra steps down By Investing.com - Investing.com
Investing.com
Why Summit Therapeutics Stock Crushed the Market This Week
The Motley Fool
Why Summit Therapeutics Stock Crushed the Market This Week - Yahoo Finance
Yahoo Finance
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Summit Therapeutics CEO acquires shares worth over $411k - Investing.com
Investing.com
Analysts Eye Summit Therapeutics' Ivonescimab As Potential Challenger To Merck's Keytruda in Lung Cancer Treatment
Benzinga
Tesla, Krispy Kreme, McCormick And Other Big Stocks Moving Higher On Tuesday
Benzinga
Analysts Eye Summit Therapeutics' Ivonescimab As Potential Challenger To Merck's Keytruda in Lung Cancer Treatment - Markets Insider
Markets Insider
Summit Therapeutics Insiders Up US$5.1m On US$5.05m Investment - Yahoo Finance
Yahoo Finance
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In ... - Markets Insider
Markets Insider
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Summit Therapeutics Showcases at Barclays Healthcare Conference - TipRanks.com - TipRanks
TipRanks
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc ... - PR Newswire
PR Newswire
SHAREHOLDER ALERT: Potential Recovery for Summit Therapeutics Inc. (SMMT) Investors - TipRanks.com - TipRanks
TipRanks
Kapitalisierung:
|
Volumen (24h):